KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to $1.2 billion.

  • Novavax's Liabilities and Shareholders Equity fell 31.10% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year decrease of 19.64%. This contributed to the annual value of $1.6 billion for FY2024, which is 13.19% down from last year.
  • Novavax's Liabilities and Shareholders Equity amounted to $1.2 billion in Q3 2025, which was down 11.72% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Novavax's Liabilities and Shareholders Equity peaked at $2.8 billion during Q1 2022, and registered a low of $1.2 billion during Q3 2025.
  • Over the past 3 years, Novavax's median Liabilities and Shareholders Equity value was $1.6 billion (recorded in 2024), while the average stood at $1.5 billion.
  • As far as peak fluctuations go, Novavax's Liabilities and Shareholders Equity skyrocketed by 695.07% in 2021, and later tumbled by 45.58% in 2023.
  • Novavax's Liabilities and Shareholders Equity (Quarterly) stood at $2.6 billion in 2021, then dropped by 12.34% to $2.3 billion in 2022, then declined by 20.42% to $1.8 billion in 2023, then fell by 13.19% to $1.6 billion in 2024, then crashed by 31.10% to $1.2 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.2 billion for Q3 2025, versus $1.3 billion for Q2 2025 and $1.3 billion for Q1 2025.